‘Global Cystic Fibrosis Market Worth $7.7bn In 2021’ Says Visiongain Report

30 August 2018
Pharma

Visiongain’s new report the Global Cystic Fibrosis Therapeutics Market 2016-2026: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies indicates that the Global Cystic Fibrosis market will see $7.7bn in spending in 2021.

The lead analyst of the report said: “The cystic fibrosis market is poised for a rapid growth year-on-year. The major driver of cystic fibrosis market is the new product launches in CFTR modulator class. The market share of CFTR modulator therapies is nearly half at 51% of the total therapeutic share in 2016. Visiongain expects the global cystic fibrosis market to grow at a very strong pace of CAGR 16.7% from 2016 until 2021. This growth is mainly driven by the expected rapid uptake of Orkambi (Vertex Pharmaceuticals).”

The 191 page report contains 113 tables, charts and graphs that add visual analysis in order to explain developing trends within the Global Cystic Fibrosis market. Visiongain provides revenue forecasts for the period 2016-2026 as well as qualitative analyses for the leading segments of this market, which include:

o Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
o Protein Transcription Modulators
o Pancreatic Enzyme Products (PEP)
o Other therapies

This report offers individual drug forecast and analysis of the 9 leading cystic fibrosis drugs. In addition, this report provides patent analysis of marketed and pipeline products for cystic fibrosis.

This 191 page report provides revenue, growth forecasts and discussion of relevant trends and developments in the leading national cystic fibrosis market. The dynamic of pricing, patient share and market share of the leading cystic fibrosis drugs in the US and Europe are also discussed.

The Global Cystic Fibrosis Therapeutics Market 2016-2026: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators, Protein Transcription Modulators, Pancreatic Enzyme Products (PEP), Other Therapies report will be of value to anyone who wants to better understand the Cystic Fibrosis market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the Cystic Fibrosis market.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever